ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
AstraZeneca announced the US availability of ZEGFROVY (sunvozertinib), the only approved oral single-agent targeted therapy for adults with previously treated EGFR exon 20 insertion-mutated NSCLC. The FDA accelerated approval was based on the WU-KONG1B trial, which showed a 46% confirmed overall response rate and 11.1-month median duration of response; continued approval is contingent on confirmatory trial benefit verification.
Key figures
- Drug Name
- ZEGFROVY (sunvozertinib)
- Phase Of Trial
- Phase III
- Diarrhea pct
- 73%
- Ild pneumonitis pct
- 1.7%
- Safety population n
- 121
- Efficacy population n
- 85
- Overall response rate
- 46%
- Responders 6mo dor pct
- 72%
- Median duration of response months
- 11.1
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.